International Society for Stem Cell Application ISSCA to Launch Postgraduate Studies Program in Stem Cell Therapies and Regenerative Medicine in Collaboration with Medicel Chile
ISSCA and Medicel, Inc. have announced plans to launch a post-graduate studies program in stem cell and regenerative medicine, to be conducted in Santiago Chile February 2021.
MIAMI, July 20 , 2020— The international Society for Stem Cell Application ISSCA and Medicel Chile have announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2020.
The program will include Seven days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Medicel’s Chief Scientific Officer and Other leading Scientists will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.
Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting
The graduate course will be scheduled 3 times during 2020 starting February 23rd
“ Our end goal in Launching this Fellowship program is to help physicians that are looking for really advanced and formal training in Cellular Therapies and Regenerative Medicine — We want to provide them the necessary skills and in depth specialization that is lacking in our smaller point of care programs ,” noted Benito Novas ISSCA Public Relations Director
To learn more about the February 2020 certification event in Santiago, or any of the other upcoming certification courses around the world, visit the ISSCA website.
About the International Society for Stem Cells Applications (ISSCA)
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine.
Incorporated and Trademarked in the United States of America as a non-profit entity, ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts. ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
About Medicel Chile
Medicel Chile is one of the premiere regenerative medicine treatment centers in the country of Chile, conveniently located in Santiago de Chile, one of the largest metropolitan areas in Latin America. Medicel carries with it a reputation as one of the most scientifically advanced and professional regenerative medicine Laboratories in Chile, and this is in no small part due to its highly-qualified team of scientists and medical professionals and advisers, who research tirelessly to head new breakthroughs in the fields of cellular therapy and cryopreservation, which is the freezing of a stem cell sample to ensure its longevity and freshness, should the patient receiving the service ever wish to use their frozen cells for some future malady.
The Stem Cell Center Network ( a Division of Global Stem Cells Group ) is an international network of regenerative medicine practitioners . Dedicated to promoting the research and development of the field of regenerative medicine, and strives to bring patients cutting-edge treatments that make use of the ever-growing list of benefits that regenerative medicine carry. This week, in a part of their effort to expand their foothold in medical communities around the world, the Stem Cell Center Network has announced the opening of a new training facility in Lisbon, Portugal.
Over the years, the Stem Cell Center Network has sought out to aggressively expand and roll out new membership opportunities, programs, events, and more– an effort that has been redoubled in the last five years. As a result, we have added members that practice regenerative medicine under our banner in over twenty five countries spread across five continents.
The new Portuguese center will be located in the clinic of Dr. Hugo Madeiras, a highly-accredited physician and scientist who will preside over the facility as the Global Stem Cells Group chief representative in Portugal. As the CEO and founder of the Clinic of Advanced Implantology, he focuses exclusively on implantology, esthetics, and digital workflows, and collaborates with over twenty doctors and seventy resources in total. He is also the clinical collaborator for the Straumann Group, a faculty which includes product testing, lecturing, and the creation and delivery of educational content.
Dr. Madeiras graduated from the Instituto Superior de Ciências da Saúde Egas Moniz in Medicine in 2007, and with a Master in Oral Rehabilitation from CESPU in 2009. With his over ten year of experience in the field, he acts as a speaker at several national and international congresses that go over developments and new treatment protocols in the field of dentistry.
“This new center will help in bringing regenerative medicine to the people of Lisbon. It will treat patients with a wide variety of different diseases, but with a special emphasis on Aesthetic Medicine,” Said Benito Novas CEO of the Global Stem Cells Group about the new Stem Cell Center Network partnership, “This new facility will be at the top of the line, a place where Portuguese doctors can come to learn about regenerative medicine protocols, and the advancements that have been made in the field. I am incredibly excited to be working in partnership with Global Stem Cells Group , and look forward to many years as a program leader here in Portugal,”
Stem Cell Center Network plans for the clinic to open in September 2020– and with that date looming closer and closer with each passing week, a date has also been agreed upon for the clinic’s inaugural training– indeed, it will be a place for doctors around the country to convene and learn, share, and research the complexities and applications of regenerative medicine. Barring any extenuating circumstances, the next first Regenerative Medicine Certification Training in the Portuguese clinic will take place on September 25 & 26th, 2020– just weeks after its formal opening. With only 10 spots available, applicants are encouraged to sign up soon for the hands-on training course.
To sign up today, visit: https://issca.us
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group announces an agreement with the South Korean biotechnology giant known as Rokit Healthcare to represent the company’s technology in the Latin American market.
The Global Stem Cells Group (GSCG) a world leader in Regenerative Medicine Technologies has signed an agreement with South Korean-based Rokit Healthcare, an esteemed bioprinter manufacturer that is committed to advancing the field of regenerative medicine and bettering the quality of life of people around the world.
The field of bioprinting is an extremely new one, but it shows great promise. Simply, it is the automated, computer aided deposition of bio-materials (which are cells, growth factors, and biocompatible polymers) for the manufacturing of functional human tissues or organs. Growth factors are harvested and used with a proprietary printing technology to create or regenerative damaged or diseased organs. Rokit Healthcare does this primarily through the proliferation of a machine that they dub an ‘organ regenerator’– it looks like a 3D printer, but instead of using plastics to create things, they use cells and materials that will be safe to implant within the human body.
The process of 3D bioprinting human tissues and organs is a revolutionary technology in the field of tissue engineering. One of the major challenges in regenerative medicine research and tissue engineering is mimicking the micro and macro environment of human tissues. In response to this challenge, advances in additive manufacturing have inspired scientists in Korea to develop novel bioprinting technology, for human tissues and organs
With the advancements of 3D printing and regenerative medicine working together, the potential is seemingly limitless for the spreading of bioprinting technology, a process that is known as 4D Printing– and Global Stem Cells Group, in an effort make this revolutionary technology available to patients, has forged an agreement with Rokit Healthcare to promote, and distribute the company’s technology in Latin America-
The Invivo 4D Printer is Rokit Healthcare’s flagship product, and it is one that revolutionizes the application of regenerative medicine and growth factor-based therapies. creating a solution for personalized and improved patient care. By leveraging a combination of 3D and bioprinting technologies, it can better distribute a patient’s autologous tissues and cells, making it an invaluable tool for those that are looking to improve the efficacy of their results, especially for certain dermatological conditions including scarring.
“We’re extremely excited about this new opportunity and look forward to working with Rokit,” Says Benito Novas, CEO of the Global Stem Cells Group, “The Invivo 4D Printer is in a position to turn the practice of regenerative medicine onto its head, and we are planning on creating a training center in Cancun, Mexico exclusively to showcase and instruct other physicians in this cutting-edge technology,”
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for regenerative medicine solutions that adhere to the highest medical standards.
About ROKIT :
ROKIT Healthcare is a global healthcare company that is committed to providing an effective and autologous organ regeneration platform. In order to undertake this daunting task, the company uses proprietary biofabrication technologies that show promise in treating several types of diseases in the field of regenerative medicine. Through the proliferation of 4D bioprinting technology, autologous stem cell technologies, ROKIT Healthcare believes that supplying an avenue for organ regeneration will drastically change the way that everyday people trust and manage their own body.
The International Society of Stem Cell Applications (ISSCA) has hereby announced the date of it’s seventh Symposium of Regenerative Medicine. As before, the organization hopes to bring together a network of regenerative medicine practitioners from all over the world to foster a growth of knowledge among them. It will go over a wide range of topics related to regenerative medicine, chiefly among them will be the response of all levels of regenerative medicine research and practice in the COVID-19 pandemic, as well as what the future looks like for the field as a result of it. In addition to this, the symposium will also cover breakthroughs in the field, new treatment options and technological developments that are now available to both doctors and patients.
Cellular Therapies During and After the Pandemic
Cellular therapies have been an invaluable asset in managing the largest pandemic in modern history. This has been evidenced by the use of Mesenchymal cells, along with other growth factors and types of cells, to treat respiratory failure and manage some of the complications induced by exposure to COVID-19. This has resulted in accelerated pathways for regulatory approval and increased funding for new regenerative medicine-based clinical trials.
We are living in a unique time for regenerative medicine, as advancements are being made month after month, year after year at a rapid, exponential rate. Keeping track of the latest advancements in this research and development, and the medical protocols that occur as a result, is critical to safeguarding lives all over the world. Every medical society’s purpose is, primarily, to promote the growth of both their members and the field that they operate in. The International Society for Stem Cell Applications (ISSCA), strives to do just that. In the interest of designing the future of cellular therapies in a post-pandemic world, ISSCA invites pioneers of the field from around the world to form and share in a platform of experiences, knowledge, and progress.
Stem Cells Group to Host Regenerative Medicine Symposium in Buenos Aires, Argentina November 28th
After a period of silence brought about by the global COVID-19 pandemic, the Global Stem Cells Group (GSCG) is prepared to begin bringing medical professionals together by hosting a Regenerative Medicine Symposium in Buenos Aires, Argentina. The Symposium will take place at the Hotel Panamericano, Buenos Aires, on the 28th of November.
The Buenos Aires symposium will feature a wide variety of educational resources, including lectures and demonstrations, as well as product information. All of this is aimed at doctors that are looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to impart the latest information on the newest compounds in the allogeneic stem cell market, including exosomes, amniotic fluid compounds, and umbilical cord blood products. Allogeneic compounds have steadily been increasing in popularity within the field of regenerative medicine, and this is due to their increased safety and treatment efficacy as research has evolved. With this in mind, GSCG representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their own practices.
ISSCA CEO Benito Novas had this to say about the upcoming event: “We’ve barely even scratched the surface of potential for regenerative medicine, which is why it’s so important that we collectively gather and learn about what we’ve done thus far. This is a South
American congress that will witness some of the greatest regenerative doctors of our time
giving once-in-a-lifetime addresses to those in attendance.”
Among these speakers are Drs. Damian Siano, Silvina Pastrana, and Maritza Novas. Dr. Siano will look specifically at sports injuries, and draw on his experience as a sports medicine specialist aiding professional athletes in the world today. Dr. Pastrana, the Medical Director of the Buenos Aires Stem Cells Center, will speak about how stem cells can help to assuage aesthetic conditions. Dr. Novas, an ISSCA Fellow in Cell Therapy and Tissue Engineering, will look at the fundamentals of stem cell biology and their clinical applications. She will cover a broad range of topics concerning MSCs during their transition from bench-side to bedside.
In addition to the wide array of educational sessions offered, the Buenos Aires symposium will also provide a wide array networking and social opportunities for those physicians in attendance. To learn more about ISSCA’s upcoming Buenos Aires Symposium, or to register for the event, visit us at: https://www.issca.us/
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to firstname.lastname@example.org